CALOSYN PHARMA, INC.
CAL-05CR, a sustained-release injectable therapeutic for osteoarthritis
- Sector
- Biotech
- Headquarters
- Shreveport, LA
- Founded
- 2007
- Latest Form D
- $750K, Mar 2024
- Total capital
- $1.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $1.5M
- 3 Form D · last Mar 2024
- 32 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$750K
- Private capital raisedForm D · SEC · 2nd filing$310K
- Private capital raisedForm D · SEC · 1st filing$400K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David WaddellDirectorNamed in SEC Form D filings
- Joseph F. LovettDirectorNamed in SEC Form D filings
- Martin BeckerExecutive Officer, DirectorNamed in SEC Form D filings
- Mike ShermanDirectorNamed in SEC Form D filings
- Richard R. BabbExecutive Officer, DirectorNamed in SEC Form D filings
- Ross BarrettDirectorNamed in SEC Form D filings
Show all 8 people
- Stephen SnowdyDirectorNamed in SEC Form D filings
- William R. GrimesExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- PendingTherapeutics And Method For Treating OsteoarthritisUSPTOApplication 19325004
- GrantedTherapeutics And Method For Treating OsteoarthritisUSPTOUS 12,433,899
- PendingTherapeutics And Method For Treating OsteoarthritisUSPTOApplication 18681818
Show all 6 patent records
- Therapeutics And Method For Treating OsteoarthritisJun 18, 2026 · Application 19325004Pending
- Therapeutics And Method For Treating OsteoarthritisOct 7, 2025 · US 12,433,899Granted
- Therapeutics And Method For Treating OsteoarthritisMay 1, 2025 · Application 18681818Pending
- Methods for Treating OsteoarthritisSep 11, 2014 · Application 14022727Pending
- Therapeutics And Methods For Treating OsteoarthritisApplication PCTUS2025014839Pending
- Therapeutics And Method For Treating OsteoarthritisApplication PCTUS2022039755Pending
Related companies, and why
- Amaryllis Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Enkefalos Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Accuitis Inc.Similar federal contract value in Biotech · null in contracts
- Hepanova, Inc.Similar federal contract value in Biotech · null in contracts
- Telos Biotech Inc.Similar federal contract value in Biotech · null in contracts
- Koniku Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .